Clinical trials
Aggression clinical trials
Below are recruiting aggression clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05928247Recruiting
Behavior program for frequent challenging behaviors in children
This trial tests a structured (manualized) assessment and treatment approach for children who have very frequent challenging behaviors despite prior help. It aims to reduce these behaviors and improve daily functioning by targeting what keeps the behavior going.
Somerset, New JerseyAges 3–17 - NCT05925101Recruiting
Studying ways to reduce frequent behavior spikes in children
This study looks at basic and applied methods to understand “extinction bursts,” times when a hard-to-control behavior may briefly get worse before it improves. It may help families and clinicians choose safer, more effective behavior supports for children with very frequent problem behaviors.
Somerset, New JerseyAges 3–17 - NCT05887973Recruiting
Youth gun violence prevention program in Washington, DC
This trial is focused on preventing firearm violence by addressing underlying causes among youth taking part in a specific DC grassroots program. If you’re a youth involved with that program in Washington, DC, this study may fit you.
Ann Arbor, MichiganAges 14–24 - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Irvine, CaliforniaAges 18 years+ - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Duarte, CaliforniaAges 18 years+ - NCT05674825RecruitingPhase 1/Phase 2
Personalized treatment using tumor test results for aggressive cancers
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
Milwaukee, WisconsinAges 18 years+ - NCT04610697Recruiting
Cognitive training for people in forensic mental health care
This trial studies whether a structured “cognitive remediation” program (training thinking skills) can help people receiving care on a forensic treatment unit. It may benefit those who want support improving attention, memory, or problem-solving as part of their treatment.
Ottawa, OntarioAges 18–55 - NCT05537610Recruiting
Test a behavior strategy for frequent self-injury
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
Somerset, New JerseyAges 3–17 - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT04732052Recruiting
tDCS treatment for adults with developmental disabilities and aggression
This trial tests whether a non-painful brain stimulation treatment (tDCS) can reduce aggressive behaviors in adults with developmental disabilities. It’s meant for people who have had aggression in the last month and can safely receive the stimulation.
Kingston, OntarioAges 18–65 - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
Duarte, CaliforniaAges 40 years+ - NCT04052048Recruiting
Active surveillance prostate cancer test registry study
This study enrolls men with low-risk prostate cancer who are either staying on active surveillance or planning surgery soon. It uses a new “SNEP assay” test to help monitor prostate cancer over time and may improve how doctors track risk.
Royal Oak, MichiganAges 40–80 - NCT04045600Recruiting
Refining communication training for kids with behavior challenges
This study tests an improved version of functional communication training for children ages 3 to 17 whose destructive behavior (like hitting or yelling) happens often and is fueled by social attention. It aims to help children learn better ways to get attention instead of using hard-to-manage behaviors.
Somerset, New JerseyAges 3–17 - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT03121001RecruitingPhase 2
Transplant from a half-matched donor for aggressive sickle cell
This Phase 2 study tests a “half-matched” stem cell transplant to treat people with aggressive sickle cell disease. It may help by replacing the blood system using stem cells from a related donor who is close but not fully matched.
Chicago, IllinoisAges 16–60
Hear when a new Aggression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for aggression?
- Yes. Clin2 currently lists 88 recruiting aggression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aggression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.